TrialGynecologic oncology2015

A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.

Robert L Coleman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.